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Abstract
Background: The problem of missing studies in meta-analysis has received much attention. Less
attention has been paid to the more serious problem of double counting of evidence.
Methods:  Various problems in overstating the precision of results from meta-analyses are
described and illustrated with examples, including papers from leading medical journals. These
problems include, but are not limited to, simple double counting of the same studies, double
counting of some aspects of the studies, inappropriate imputation of results, and assigning spurious
precision to individual studies.
Results: Some suggestions are made as to how the quality and reliability of meta-analysis can be
improved. It is proposed that the key to quality in meta-analysis lies in the results being transparent
and checkable.
Conclusion: Existing quality check lists for meta-analysis do little to encourage an appropriate
attitude to combining evidence and to statistical analysis. Journals and other relevant organisations
should encourage authors to make data available and make methods explicit. They should also act
promptly to withdraw meta-analyses when mistakes are found.
Background
We live in an age of meta-analysis and would-be meta-
analysts are constantly exhorted to find all the evidence. A
popular tool for evaluating the quality of meta-analysis
places great stress on the efforts that have been made to
find all the relevant studies and the extent to which these
efforts have been described [1,2]. Meta-analysts are
advised to use funnel plots [3] or other similar devices in
an attempt to establish if there has been any publication
bias in favour of significant results and to calculate how
many missing studies it would take to overturn their con-
clusions [4].
The reverse problem, however, of finding evidence that
isn't there has received rather less attention, yet is surely
just as, if not more, serious.
Methods
In this article I describe various species of this problem,
illustrating it with examples from leading medical jour-
nals, including The Journal of the American Medical Associa-
tion (JAMA), The British Medical Journal(BMJ), The Lancet
and The New England Journal of Medicine (NEJM). There is
no attempt to quantify the extent of this problem except
by remarking that it has not been particularly difficult to
find the examples I have found. However, it is hoped that
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the examples will serve a useful purpose in putting would-
be meta-analysts on their guard. Once the examples have
been presented I shall offer some speculative remarks as to
what factors might pre-dispose towards the problems
exemplified and what might be done to improve the situ-
ation.
In choosing and presenting these examples, I should
make one point clear. They are not being chosen to exem-
plify authorial incompetence. In fact many of the authors
of the papers I discuss are rightly acknowledged as leading
experts in the field of meta-analysis and most of the
papers chosen are impressive in many respects. On the
contrary, I shall argue in due course, that the problem is
one that cannot be cured by trust. The cure is in transpar-
ency. As such, tools for evaluating the quality of meta-
analyses are largely irrelevant. What is necessary is to
make it easy to check the claims.
Results
Simple double counting of studies
A recent meta-analysis of the safety of anticholinergics in
chronic obstructive pulmonary disease (COPD) by Singh
et al [5] in JAMA affords an example. A problem with this
meta-analysis are that studies were counted twice. For
example, a publication by Brusasco et al was included [6].
However, this publication was itself a meta-analysis of
two-studies [7] one of which, by Donohue et al [8], was
also separately included by Singh et al. Thus the Donohue
et al study was included twice, which is clearly inappropri-
ate.
Double counting of some aspects of studies
This error is slightly more subtle. Again JAMA affords an
example. A meta-analysis by Kozyrskyj et al compared
short and long course treatment of otitis media with anti-
biotics [9]. An unsatisfactory feature of this overview is
that arms of the same study are counted more than once
[10]. A number of the trials being summarised had more
than two arms. The way that the authors chose to deal
with this was to enter the control arm twice. Thus (say)
treatment A was compared to C and then treatment B
(say) was compared to C. The net effect was that C was
counted twice.
For example, a trial by Hoberman et al [11] was included
twice, apparently once with 375 patients and once with
386. However, the original data refer to two long courses
of antibiotics in 178 and 189 patients respectively and to
one short course with 197 patients. It appears that this
short course has been counted twice by Kozyrskyj et al so
that we have 178+197 = 375 and 189+197 = 386. This sort
of double counting seems to have occurred on at least
three occasions.
A similar case appears in the meta-analysis by Brockle-
bank [12] et al in the BMJ comparing metered dose inhal-
ers (MDI) and other hand held devices for delivering
corticosteroids in asthma. Figure 2 of that paper includes
what appear to be two studies by Vidgren et al. In fact,
there is only one study, a three armed cross-over trial[13]
comparing Diskhaler®, Easyhaler® and an MDI. Presuma-
bly, the data for the MDI have been included twice in the
overall summary.
A slightly different form of a double counting of some
information from a study occurs in the paper by Singh et
al [5] already cited. Two studies by Casaburi [14,15] are
included in the meta-analysis. However one was a prelim-
inary report on short term results and the other is the full
report at conclusion, including the short term data. Thus
the short term data must have been counted twice.
Accepting implausible claims for the precision of individual 
studies
A meta-analysis by Hackshaw et al [16] in the BMJ consid-
ered passive smoking. The method involved weighting
reported log-odds ratios using reported (or calculated
from confidence intervals) standard errors. However,
Peter Lee, in an extremely important but sadly neglected
article [17] in Statistics in Medicine has pointed out that the
fact that the standard error for a log-odds ratio is approxi-
mately equal to the square root of the sum of the recipro-
cals of the frequencies in the corresponding four-fold
table provides various lower bounds on the standard
error. Conversely, a given standard error implies a mini-
mum sample size. In fact for a given total sample size N,
the split of cases and non-cases in exposed and unexposed
groups that gives rise to the minimum standard error is an
equal split of N/4 subjects in each cell. It follows, for
example, that for any reported variance, V the total sample
size, N must satisfy the requirement that N ≥ 16/V. Similar
inequalities exist for the total of any two cells and for the
numbers in any given cell.
As Lee showed [17], at least one of the studies [18]
included by Hackshaw et al [16] in their meta-analysis has
impossibly low standard errors when examined in this
way: the numbers of subjects are too few in view of the
precision claimed.
Imputing data
The meta-analysis by Brockelbank et al [12] already cited
has ten within-arm within-study standard deviations
equal to 100.0. There is no explanation of this fact and it
appears that these standard deviations are imputed. In fact
cross-over studies are being combined and it seems that
the authors are forcing them into the parallel group frame-
work that RevMan, the Cochrane Collaboration software
required (at least in its earlier versions). In order to do thisBMC Medical Research Methodology 2009, 9:10 http://www.biomedcentral.com/1471-2288/9/10
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they have invented between-patient standard deviations
that are, in fact, irrelevant to judging the outcome from a
cross-over trial.
This is, in my view, a bad idea, although, it must be
granted that this is a far less serious error than some others
described, since, if anything, the evidence from the cross-
over studies is likely to be understated since between-
patient standard deviations are used. Nevertheless, it is an
inappropriate approach that should be avoided.
However, not all attempts to impute data understate the
evidence. For example, Nicholson et al [19], in a meta-
analysis of depression as a prognostic factor in heart dis-
ease were able to identify 54 relevant studies. Unfortu-
nately, six of these only recorded a lack of a significant
association and did not give confidence intervals. Nichol-
son et al imputed an effect estimate of one to the studies
and estimated the standard errors by regression on the
number of patients.
This procedure cannot be endorsed. The value of unity
chosen is the value that gives the least possible association
but this overstates the lack of association. For example, a
study by Hallstrom [20], that enrolled 795 women for 12
years follow up but for which only the result 'not signifi-
cant' is available is awarded a relative risk (RR) of 1.0 with
a confidence interval 0.6 to 1.7. However, the study by
Ferketich [21] which is based on 5007 women followed
for ten years has a reported RR of 1.0 with a wider confi-
dence interval of 0.5 to 2.0. It is surely not appropriate to
give a smaller study for which the relevant data have had
to be guesstimated more weight than a larger one for
which the data are available.
It would have been better in my opinion to have excluded
the six studies with insufficient detail altogether.
Spurious precision of individual trials
An interesting paper by Peters et al [22] considered Baye-
sian approaches to combining epidemiological observa-
tional data on humans with experimental data in animals
and illustrated this using an investigation of trihalometh-
ane exposure as a possible cause of low birthweight. They
identified five epidemiological and eight toxicological
studies in animals. However, in analysing the toxicologi-
cal studies they treated the pups in litters of rats as inde-
pendent observations rather than treating them as
repeated measures on the dams. Since the number of
pups, is of course, much higher than the number of dams
this has the consequence of 'spurious precision' [23,24].
In other words, there is an overstating of the evidence.
Inappropriate pooling of treatments
A very thorough and in many ways expert meta-analysis
by Jüni et al in the Lancet looked at the risk of cardiovas-
cular events under rofecoxib [25]. A number of different
treatments, including placebo, naproxen and non-
naproxen non-steroidal anti-inflammatory drug (NSAID)
were considered as controls. Thus the meta-analysis com-
pares rofecoxib to a mixture of controls. This is not, in
itself illegitimate but one has to be quite clear about the
purpose of such a meta-analysis. The relevant null
hypothesis is 'rofecoxib is identical to all these compara-
tors'. If and when this null hypothesis is rejected the alter-
native hypothesis that then follows is 'rofecoxib is
different from at least one of these comparators'.
Jüni et al, were criticised by researchers at Merck, the mak-
ers of rofecoxib, for contravening a basic principle of
meta-analysis, namely to pool like with like [26]. I disa-
gree that there is such a principle. However, I also disagree
with a conclusion that Jüni et al drew from their analysis.
They implied that their meta-analysis showed that
rofecoxib was different to each comparator, including pla-
cebo, and indeed that this was already clear from data
available by 2000. However to be able to assert this alter-
native hypothesis, it is necessary to have tested rofecoxib
separately against each comparator and for such a meta-
analysis the comparators cannot be pooled. In order to
justify this claim, they carried out 'a test of interaction' for
treatment effect by type of comparator (placebo,
naproxen or non-naproxen NSAID) and used a non-sig-
nificant result to justify pooling. (See, for example, table 2
of that paper.)
However, there are a number of problems with this proce-
dure. The first is that the term interaction is misleading. It
is actually main effects (for example the difference between
naproxen and placebo) that it is necessary to prove are
zero. This is important, since the situation is qualitatively
different from a genuine test of interaction involving trials
of different type, or patients of a different sort, as a stra-
tum where the same treatment and control is being com-
pared [27]. Under such circumstances it is a higher order
effect (the interaction) that is assumed zero until proof to
the contrary is available. Here it is an effect that is of the
same order (placebo – naproxen) as the effect being exam-
ined (rofecoxib-naproxen) that is assumed to be zero.
Secondly, absence of evidence is not evidence of absence.
Had Jüni et al wished to use the extremely large amount
of information comparing rofecoxib to naproxen to pro-
duce a comparison to placebo they should have used the
formal method of the putative placebo [28,29].BMC Medical Research Methodology 2009, 9:10 http://www.biomedcentral.com/1471-2288/9/10
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Thirdly, it  is clear that this procedure is easily abused.
Given a great deal of data showing that treatment A (say)
is better than control C (say), a small trial inadequately
comparing treatment A to B would fail to show a signifi-
cant 'interaction' and entitle one to pool B and A and use
the combined data to prove that B was better than C.
I cannot leave this example, however, without pointing
out that I do not believe that the fact that an advantage of
naproxen to rofecoxib is not proof of a disadvantage of
rofecoxib compared to placebo lets Merck, the developers
of rofecoxib, off the hook. The gastric benefits of rofecoxib
compared to naproxen were clearly shown in the same
study [30] in 2000 that showed the cardiovascular bene-
fits of naproxen to rofecoxib. From that point onwards
patients should have been informed that one net benefit
was being traded against another, whatever the explana-
tion of either.
Numerical slips
This is a sin to which I must plead guilty myself on occa-
sion. Indeed, it is inherent to all scientific work that mis-
takes are made from time to time and are likely to be
perpetuated. A beautifully described example comes in
Primo Levi's essay 'Chromium' in The Periodic Table [31]
in which, in a piece of chemical and statistical detection,
he becomes suspicious of an unchallenged recipe that
requires the addition of 'twenty-three drops of a certain
reagent'. Eventually he finds an old file card bearing 'the
direction to add "2 or 3" drops and not "23"'(p131).
In a discussion of Bayesian approaches to specifying prior
distributions for random effect variances Lambert et al
[32] used the data from Kozyrskij [9] to illustrate the
problems with random effects analyses. I presented a fre-
quentist alternative based on using proc nlmixed® of SAS®
but what I did not realise at the time was that I had coded
the main effects of the trials inappropriately. (It was my
colleague Jim Weir who subsequently discovered my mis-
take.) Thus, where I claimed a point estimate of 0.39 with
a standard error of 0.20, a corrected analysis gives 0.42
with a standard error of 0.19. The difference is small in
this case but that is at least partly a matter of luck.
Incomplete reporting
This is a rather different problem. There are a number of
reported meta-analyses where it simply is almost impossi-
ble to check the authors' results with certainty. In particu-
lar where the following combination applies, that neither
the method of statistical analysis is specified nor are the
data from the original study fully available, then a great
deal has to be taken on faith. The problem then becomes
analogous to one of hearsay evidence in court. What is
asserted may well be true but it is very difficult to call any-
body to account to establish its reliability.
Consider, for example, a paper by Hrjobartson and
Gotszche in the NEJM [33] which, considers the efficacy
of placebos. This is an extremely interesting investigation
that I have referred to elsewhere very positively [34] that
points out that to establish the efficacy of placebo to the
same degree of proof we require for standard treatments
we need trials which have a control group for the placebo,
that is to say no treatment. The authors perform a meta-
analysis of all the three armed trials (treatment, placebo,
no treatment) they can find. An appendix, available on
the website gives results but neither it nor the main paper
actually details the methods in sufficient detail for the
results to be reproduced.
It might be thought that detailing the method is superflu-
ous. In fact, however, there is a bewildering array of tech-
niques possible for conducting a meta-analysis. In my
paper The Many Modes of Meta [35] I identified three major
data types: all studies used the same outcome and raw
data are available, the same outcome but summary data
only and different outcomes in different studies. I also
identified at least nine different philosophical approaches
that could be used to analyse summary measures. Many of
these nine different approaches could be implemented in
different ways. For example, in deciding to analyse binary
data, one has to make a choice of risk scale: risk difference,
relative risk, odds ratio. A much-cited paper by New-
combe [36] compares eleven different approaches to esti-
mating confidence intervals for a risk difference for a
single trial. In other words there are dozens of ways that
binary meta-analyses alone could be performed.
Discussion
What these examples show is that neither competence of
the authors not prestige of the journal is any guarantee
that the results of a meta-analysis do not need checking.
Expert authors make mistakes that the review process does
not correct. It therefore follows that an important stand-
ard by which a meta-analysis is to be judged is checkabil-
ity. I propose that the following five points should be
adopted by the community of meta-analysts and users if
we are to improve the reliability of meta-analysis.
1. Be vigilant about double counting.
2. Make results checkable.
3. Describe approaches to analysis in detail.
4. Judge the meta-analysis not the analyst.
5. Create a culture of correction.
As regards the first of these, I hope that I have given suffi-
cient examples to put potential users on guard. AlthoughBMC Medical Research Methodology 2009, 9:10 http://www.biomedcentral.com/1471-2288/9/10
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I consider that quality checklists, however good, are of lit-
tle relevance when deciding whether to trust a meta-anal-
ysis, they are potentially useful in warning would-be
analysts what to consider. In this respect, however, the
current favourite, the Oxman and Guyatt score, is quite
inadequate as it does not warn the user of potential prob-
lems. Furthermore it has a bias in favour of inclusion. The
ten points included (see Oxman et al [2] page 1272), are
1. Were the search methods reported?
2. Was the search comprehensive?
3. Were the inclusion criteria reported?
4. Was selection bias avoided?
5. Were the validity criteria reported?
6. Was validity assessed appropriately?
7. Were the methods used to combine studies reported?
8. Were the findings combined appropriately?
9. Were the conclusions supported by the reported data?
10. What was the overall scientific quality of the overview?
Of the points, one, point 2, explicitly stresses the impor-
tance of being comprehensive and five (points 1,3,4,5 and
6) also address inclusion, whereas it would have to be a
researcher who was already sensitised to the problem of
double counting (say) who took point 8 as being a
reminder to pay attention to this.
The implementation of my second proposal is partly con-
strained by resources. One inherent advantage that meta-
analyses of the Cochrane Collaboration have over others
is the amount of space that is allowed compared to jour-
nals. This is a point in their favour. However technological
advances are making it easier for journals to match this
through supplementary material provided on the web and
this is what we have to strive for.
The third point requires a recognition and acceptance that
meta-analysis is, contrary to what is sometimes main-
tained, not simple after all. It is not just a question of
pushing data into some software sausage machine and
waiting for a summary to appear. Empowering the statis-
tically innocent to perform statistical analyses has its
drawbacks. Many choices have to be made along the way
and not all are uncontroversial. In consequence it is nec-
essary to describe those choices in some detail.
The fourth point is that we should recognise that even
experts can make mistakes and even those with motives
we mistrust can have good arguments. There is a rather
silly secondary literature of meta-analysis that seeks to
award quality points for overviews from this or that
source. Even if the quality instruments being used were
appropriate (and they are not) the false positives and neg-
atives in any screening procedure based on such class
scores would be so numerous as to make the information
nearly worthless in judging whether to trust an individual
analysis. Consider the case of Lee's checks [17] and Hack-
shaw et al's meta-analysis [16]. Lee works as a consultant
to the tobacco industry – enough reason to distrust him
when passive smoking is being discussed, many would
say. Hackshaw et al are public health experts with a con-
siderable reputation. Enough grounds to trust them, many
(including me) would claim. However, the trust or mis-
trust we have in the meta-analysts is irrelevant once we
have got to the point of debating a scientific issue such as
whether a quoted standard error must be too small.
My final point is that journals should devote more space
to the correction of previous work and that we need a
mechanism for flagging problems with papers once iden-
tified. For example, as far as I am aware, the BMJ has not
issued notes correcting either of the two meta-analyses
[12,37] mentioned in this article, despite the fact that the
problems have been pointed out to the editors. Peter Lee
[17] drew attention in Statistics in Medicine (SiM) to the
problem with the BMJ paper on passive smoking but a
recent paper [38] in SiM not only does not cite Lee but
cites the paper on passive smoking and uses it to illustrate
a method to deal with missing studies, the opposite of the
known problem! The editors of the Journal of The Royal Sta-
tistical Society Series C refused to publish a letter by Andy
Grieve and me pointing to some problems with Peters et
al [22], including that mentioned here. Over two years
after I informed the Cochrane Collaboration regarding the
double counting in the otitis media meta-analysis [39],
there is still no correction. The editors of JAMA initially
declined to take any action regarding the corresponding
paper [9] when I brought it to their attention and I still
wait to see what they will do about it.
Conclusion
What is needed is an awareness that scientific progress
occurs through an ongoing, vigorous process of debate
and criticism and not through the piling up of incontro-
vertible facts. We must be prepared to check and correct (if
necessary) published results and they must be published
in a way that makes this easy.
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